Fungi: mycelia, mushrooms & more

122 readers

56 users here now

This is a community for information and discussions on

Mycorrhizal networks
Mycoremediation for land restoration, water mycofiltration etc
Biodegradable mycelium-based materials (building blocks, textiles, alternatives to plastic, to name a few)
Fungal technology & biotechnology
Medicinal uses

And so much more.

Some related local communities

Credits

Icon: Studio Klarenbeek & Dros
Banner: Pauline Moss

founded 2 months ago

MODERATORS

solo

High dose psilocybin shows similar antidepressant effects to escitalopram (www.news-medical.net)

submitted 1 month ago by solo to c/fungus

7 comments fedilink hide all child comments

you are viewing a single comment's thread
view the rest of the comments

[–] booly@sh.itjust.works 2 points 1 month ago

What's the incentive for pharma companies to develop a cheap and safe alternative to their poison?

The exclusive rights to get their product administered in hospitals, carried by pharmacies, etc.

The drug company Lykos funded studies into MDMA/ecstasy/Molly as PTSD treatment, and submitted an application for being the exclusive licensed provider of MDMA. Now, the studies were rejected, but mainly because of sloppy science. If they had the evidence showing it actually works, they would've gotten the exclusive right to mass produce it in the U.S.

That's worth a lot of money, even if it is a relatively cheap drug. And if there's exclusivity, they can set the price wherever they want, where the cheapness of the manufacturing is actually a plus for the manufacturer.